Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD

What Was Tested

This randomized controlled trial paper looks at ANP (Atrial Natriuretic Peptide).

CKD is an important risk factor for cardiac surgery.

Who Took Part

The abstract describes 303 patients taking part.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

This was a randomized controlled study of 303 patients with CKD who underwent CABG, and were divided into a group who received carperitide infusion and another group without carperitide.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got ANP (Atrial Natriuretic Peptide) and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received ANP (Atrial Natriuretic Peptide).

The primary endpoints were: 1) the post-operative dialysis-free rate; and 2) serum creatinine (sCr) and estimated glomerular filtration rate.

What Was Measured

Topics PubMed links to this paper include Atrial Natriuretic Factor, Cardiovascular Diseases, Coronary Artery Bypass, Hospitals, University, Kidney Failure, Chronic and Renal Dialysis.

What This Means in Plain Language

The paper is a randomized and double-blind study of ANP (Atrial Natriuretic Peptide) in 303 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (Journal of the American College of Cardiology), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.